EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Ponsegromab for the Treatment of Cancer Cachexia

John D Groarke, Jeffrey Crawford, Susie M Collins, Shannon Lubaczewski, Eric J Roeland, Tateaki Naito iD, Andrew E Hendifar, Marie Fallon, Koichi Takayama, Timothy Asmis, Richard F Dunne, Isik Karahanoglu und 5 weitere

New England Journal of Medicine · 19.12.2024 · 391 (24) · 2291-2303

DOI: 10.1056/nejmoa2409515 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 19.12.2024. Verfasst von John D Groarke und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Internal Medicine Research Unit (J.D.G., I.K., M.A.H., A.R.S.) and Clinical Pharmacology (R.Q.), Pfizer, Cambridge, MA; Duke Cancer Institut…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Appetite, Cachexia, Growth Differentiation Factor 15. Die Arbeit wurde bisher 359-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Cancer Research UK, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAppetiteCachexiaGrowth Differentiation Factor 15NeoplasmsAgedFemaleHumansMaleMiddle AgedBody WeightDouble-Blind MethodExerciseInjections, Subcutaneous

Substanzen

Antibodies, Monoclonal, HumanizedGDF15 protein, humanGrowth Differentiation Factor 15

Autor:innen und Institutionen

  • From the Internal Medicine Research Unit (J.D.G., I.K., M.A.H., A.R.S.) and Clinical Pharmacology (R.Q.), Pfizer, Cambridge, MA; Duke Cancer Institute, Duke University Medical Center, Durham, NC (J.C.); Global Biometric…

ORCID-Profile: Tateaki Naito

Förderung

  • Cancer Research UK
  • Pfizer

Zitieren

APA

Groarke, J. D., Crawford, J., Collins, S. M., Lubaczewski, S., Roeland, E. J., Naito, T., Hendifar, A. E., Fallon, M., Takayama, K., Asmis, T., Dunne, R. F., Karahanoglu, I., Northcott, C. A., Harrington, M. A., Rossulek, M., Qiu, R., & Saxena, A. R. (2024). Ponsegromab for the Treatment of Cancer Cachexia. New England Journal of Medicine, 391(24), 2291-2303. https://doi.org/10.1056/nejmoa2409515

Vancouver

Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, et al. Ponsegromab for the Treatment of Cancer Cachexia. New England Journal of Medicine. 2024;391(24):2291-2303. doi:10.1056/nejmoa2409515

BibTeX
@article{Groarke2024,
  author = {Groarke, John D and Crawford, Jeffrey and Collins, Susie M and Lubaczewski, Shannon and Roeland, Eric J and Naito, Tateaki and Hendifar, Andrew E and Fallon, Marie and Takayama, Koichi and Asmis, Timothy and Dunne, Richard F and Karahanoglu, Isik and Northcott, Carrie A and Harrington, Magdalena A and Rossulek, Michelle and Qiu, Ruolun and Saxena, Aditi R},
  title = {Ponsegromab for the Treatment of Cancer Cachexia},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {24},
  pages = {2291--2303},
  doi = {10.1056/nejmoa2409515}
}
Kostenlos starten →